Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation: a Randomized, Single-blind, Multicenter Exploratory, Heparin-controlled Trial

NCT05555641 is registered in ClinicalTrials.gov with Xiaobo Yang, MD as lead sponsor.

NCT NCT05555641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05555641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation: a Randomized, Single-blind, Multicenter Exploratory, Heparin-controlled Trial
Lead sponsor
Xiaobo Yang, MD
Phase
Phase 2
Overall status
Unknown status
Start date
December 20, 2022
Completion date
October 1, 2024
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulation, critical illness